olivLaw · US equity research
Praxis Precision Medicines, Inc. PRAX
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
Praxis Precision Medicines is a neuroscience company developing therapies for central nervous system disorders, starting from the genetics of epilepsy. In 2026 it is preparing its first commercial launches, with ulixacaltamide for essential tremor and relutrigine for developmental epileptic encephalopathies, while its net loss rose to 176.3 million USD in the first six months of the year. The company reported about 1.4 billion USD in cash and investments at June 30, 2026, a reserve that, according to its statements, covers operations into 2028.
At the close of 05 Nov 2026, Praxis Precision Medicines, Inc. (PRAX) stock was 262.59 USD (−7.80% on the day), with market capitalisation 7.3 bn USD, beta 0.95, 52-week range 164.09–386.33 USD. Latest reported quarter (Q2 2026): net income of -83.7 m USD, diluted EPS -2.87 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 43.7
- weak (30–45)
- Bollinger (20, 2)
- 233.45 – 293.90
- in the lower half of the band · %B 0.48 · band width 22.9%
- SMA 50 / 200
- 293.54 / 314.09
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -2.68 / -6.11
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −6.3% | −5.9% | −0.3 pp | — |
| 3 months | −29.1% | −4.6% | −24.4 pp | — |
| 6 months | −21.2% | +0.2% | −21.4 pp | — |
| Year to date | −10.9% | +7.4% | −18.3 pp | — |
| 1 year | +59.5% | +8.2% | +51.3 pp | +13.7% |
| 3 years | +1,675.5% | +68.4% | +1,607.0 pp | +19.7% |
| 5 years | −20.9% | +56.5% | −77.4 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 302.0 k | 7.5 m | 0 | 0 | 0 | 0 | — | — |
| Research & development | 41.9 m | 56.3 m | 60.8 m | 63.0 m | 65.8 m | 77.5 m | 78.0 m | 69.4 m |
| Operating income | -56.8 m | -64.0 m | -74.7 m | -76.1 m | -78.4 m | -97.0 m | -105.9 m | -96.9 m |
| Net income | -51.9 m | -58.7 m | -69.3 m | -71.1 m | -73.9 m | -88.9 m | -92.6 m | -83.7 m |
| Diluted EPS | -2.75 | -2.94 ≈ | -3.29 | -3.31 | -3.36 | -3.49 ≈ | -3.20 | -2.87 |
| Operating cash flow | -27.5 m ≈ | -56.1 m | -53.0 m | -54.7 m ≈ | -65.1 m ≈ | -76.3 m | -86.2 m | -77.5 m ≈ |
| Capex | 0 ≈ | 0 | 0 | 56.0 k ≈ | 0 ≈ | 0 | 62.0 k | 245.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | unavailable | unavailable | unavailable | 0 | 2.4 m | 8.6 m | 0 |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | +249.5% | −100.0% |
| Net income | -35.5 m | -61.8 m | -167.1 m | -214.0 m | -123.3 m | -182.8 m | -303.3 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -7.86 | -3.94 | -69.65 | -18.69 | -10.21 | -13.48 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable | unavailable | -5,037.9% | -2,137.5% | unavailable |
| Free cash flow | -33.5 m | -52.6 m | -125.6 m | -185.5 m | -111.2 m | -131.8 m | -249.1 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 357.3 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 878.1 m USD
- Total assets
- 937.9 m USD
- Debt / equity
- unavailable
- Current ratio
- 10.22x
- ROE
- -45.8%
- ROA
- -42.7%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 2.4 m | 8.6 m | 0 | SEC (XBRL)· 19 Feb 2026verified |
| Research & development | 45.0 m | 120.3 m | 155.0 m | 86.8 m | 152.4 m | 267.1 m | SEC (XBRL)· 19 Feb 2026verified |
| Operating income | -62.0 m | -167.3 m | -215.0 m | -126.4 m | -200.2 m | -326.2 m | SEC (XBRL)· 19 Feb 2026verified |
| Pre-tax income | -61.8 m | -167.1 m | — | -123.0 m | -182.7 m | -302.8 m | SEC (XBRL)· 19 Feb 2026verified |
| Income tax | -8.0 k | 0 | — | — | — | 471.0 k | SEC (XBRL)· 19 Feb 2026verified |
| Net income | -61.8 m | -167.1 m | -214.0 m | -123.3 m | -182.8 m | -303.3 m | SEC (XBRL)· 19 Feb 2026verified |
| Diluted EPS | -7.86 | -3.94 | -69.65 | -18.69 | -10.21 | -13.48 | SEC (XBRL)· 19 Feb 2026verified |
| Weighted average diluted shares | 9.0 m | 42.5 m | 3.1 m | 6.6 m | 17.9 m | 22.5 m | SEC (XBRL)· 19 Feb 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 296.6 m | 138.7 m | 61.6 m | 81.3 m | 215.4 m | 357.3 m | SEC (XBRL)· 19 Feb 2026verified |
| Current assets | 302.3 m | 287.4 m | 110.8 m | 84.9 m | 404.4 m | 610.9 m | SEC (XBRL)· 19 Feb 2026verified |
| Property, plant & equipment, net | 82.0 k | 1.2 m | 971.0 k | 588.0 k | 230.0 k | 147.0 k | SEC (XBRL)· 19 Feb 2026verified |
| Intangibles (excl. goodwill) | — | — | — | — | — | 0 | SEC (XBRL)· 06 Aug 2026verified |
| Total assets | 303.2 m | 292.7 m | 115.1 m | 87.9 m | 483.1 m | 937.9 m | SEC (XBRL)· 19 Feb 2026verified |
| Accounts payable | 4.1 m | 10.8 m | 14.7 m | 5.8 m | 12.5 m | 24.6 m | SEC (XBRL)· 19 Feb 2026verified |
| Current liabilities | 15.7 m | 38.4 m | 34.3 m | 15.7 m | 37.6 m | 59.8 m | SEC (XBRL)· 19 Feb 2026verified |
| Total liabilities | 15.7 m | 41.9 m | 39.0 m | 18.3 m | 37.7 m | 59.8 m | SEC (XBRL)· 19 Feb 2026verified |
| Equity | 287.5 m † | 250.8 m † | 76.1 m † | 69.7 m † | 445.5 m † | 878.1 m † | SEC (XBRL)· 19 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -52.6 m | -124.6 m | -185.0 m | -111.1 m | -131.8 m | -249.1 m | SEC (XBRL)· 19 Feb 2026verified |
| Capex | 0 | 1.1 m | 444.0 k | 50.0 k | 0 | 56.0 k | SEC (XBRL)· 19 Feb 2026verified |
| Free cash flow | -52.6 m ≈ | -125.6 m ≈ | -185.5 m ≈ | -111.2 m ≈ | -131.8 m ≈ | -249.1 m ≈ | SEC (XBRL)· 19 Feb 2026derived |
| Investing cash flow | 0 | -140.5 m | 96.9 m | 39.0 m | -248.5 m | -311.1 m | SEC (XBRL)· 19 Feb 2026verified |
| Financing cash flow | 304.4 m | 107.6 m | 10.5 m | 91.9 m | 514.3 m | 702.2 m | SEC (XBRL)· 19 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 12.5% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 7.3 bn USD
Key indicators
Coverage and freshness
Score by group
13% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 15.7x | 100 (on a fixed band) | 33% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -4.2% | 0 (on a fixed band) | 67% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
PRAXIS PRECISION MEDICINES, INC. (PRAX). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 0 USD in 2025; YoY growth -100.0%; ROE -38.9%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 15.7x
What contradicts it
- FCF yield: -4.2%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,283.9 bn | 44.3 | 86.1% | 31.9% | +44.7% | +27% / +131% |
| JNJJohnson & Johnson | 655.6 bn | 41.3 | 20.0% | 16.2% | +6.0% | +32% / +76% |
| ONCBeone Medicines Ltd. | 575.0 bn | 640.9 | 18.4% | 13.9% | +40.2% | +14% / +107% |
| ABBVAbbVie Inc. | 509.5 bn | 49.6 | — | 15.7% | +8.6% | +27% / +102% |
| MRKMerck & Co., Inc. | 362.2 bn | 151.2 | 5.1% | 3.6% | +1.3% | +40% / +43% |
| ABTAbbott Laboratories | 196.7 bn | 42.3 | 9.2% | 9.7% | +5.7% | −12% / +9% |
| PFEPfizer Inc | 170.3 bn | 42.6 | 4.4% | 6.3% | −1.6% | +16% / −2% |
| VRTXVertex Pharmaceuticals Inc | 137.5 bn | 34.9 | 20.8% | 30.7% | +8.9% | +25% / +53% |
| BMYBristol-Myers Squibb Company | 129.0 bn | 14.0 | 44.1% | 18.5% | −0.2% | +28% / +28% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.3 | 6.6% | 3.6% | +4.3% | +55% / +325% |
| ZTSZoetis Inc. | 33.4 bn | 13.8 | 57.6% | 26.4% | +2.3% | −36% / −54% |
| ROIVRoivant Sciences Ltd. | 26.5 bn | — | -6.2% | -3,535.0% | −71.6% | +76% / +283% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 24.1 bn | 21.3 | 19.1% | 38.6% | +10.6% | +16% / +136% |
| INSMInsmed Inc | 23.9 bn | — | -72.5% | -39.9% | +66.7% | −48% / +335% |
| VTRSViatris Inc. | 21.7 bn | — | -24.3% | -23.9% | −3.0% | +77% / +107% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.0 bn | 7.9 | 126.6% | 52.8% | +65.2% | −65% / −7% |
| JAZZJazz Pharmaceuticals plc | 14.6 bn | 74.1 | 5.1% | 4.4% | +4.9% | +29% / +92% |
| PRAXPraxis Precision Medicines, Inc. | 7.3 bn | — | -38.9% | — | −100.0% | +59% / +1,675% |
| TVTXTravere Therapeutics, Inc. | 4.7 bn | — | -252.7% | -18.7% | +110.5% | +38% / +678% |
| LQDALiquidia Corporation | 4.0 bn | 32.1 | 131.8% | 30.7% | +1,031.2% | +36% / +521% |
| ABCLAbCellera Biologics Inc. | 3.4 bn | — | -17.3% | -248.8% | +160.6% | +198% / +136% |
| BHCBausch Health Companies Inc. | 3.0 bn | — | — | -7.6% | +6.7% | +25% / +11% |
| PRGOPerrigo Company plc | 2.2 bn | — | -51.4% | -43.3% | −2.8% | +18% / −48% |
| SRPTSarepta Therapeutics, Inc. | 1.9 bn | — | -7.6% | -5.9% | +15.6% | −18% / −78% |
1- and 3-year price returns: for PRAX from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Praxis Precision Medicines is a neuroscience company developing therapies for central nervous system disorders, starting from the genetics of epilepsy. In 2026 it is preparing its first commercial launches, with ulixacaltamide for essential tremor and relutrigine for developmental epileptic encephalopathies, while its net loss rose to 176.3 million USD in the first six months of the year. The company reported about 1.4 billion USD in cash and investments at June 30, 2026, a reserve that, according to its statements, covers operations into 2028 23.
SWOT
Strengths
- A diversified clinical portfolio with four late-stage candidates and two proprietary platforms based on epilepsy genetics 12.
- Substantial financial reserves and a declared funding runway into 2028, which provides time to prepare launches 3.
- Designations received from the FDA for several candidates, including elsunersen 23.
Weaknesses
- The company has no approved products and has generated no product sales, which makes future performance hard to assess 1.
- Net losses have grown year over year and continue to rise as administrative and personnel costs expand 13.
- A key vormatrigine study missed its primary endpoint, which led to a reassessment of the program 23.
Opportunities
- Approval of ulixacaltamide could open a market for patients with essential tremor who lack an effective treatment 13.
- The EMERALD study in developmental epileptic encephalopathies could extend relutrigine's indications if results are positive 23.
- A transdermal formulation of ulixacaltamide under collaboration could broaden the eligible patient population 3.
Threats
- Regulatory delays, such as the extended review period, could postpone planned launches 23.
- Reliance on repeated share issuances could dilute existing shareholders if other funding becomes difficult 1.
- Competition from existing treatments and therapies in development could limit adoption of the company's products 1.
Risks
- No approved productshigh
The company has not yet obtained any marketing authorization and has no product revenue, so success depends on future approvals 1.
- Uncertain clinical resultshigh
A primary endpoint of the POWER1 study was not met, and clinical development can produce unfavorable results at any stage 23.
- Need for additional fundingmedium
The company states its current reserve lasts into 2028, but expenses could rise faster if delays or unexpected costs occur 1.
- Shareholder dilutionmedium
Share issuances used for funding can reduce existing shareholders' ownership and may introduce liquidation preferences 1.
- Regulatory timeline delayslow
The extension of the review period for the relutrigine NDA shows that target dates can change, which may affect launch planning 23.
Investment thesis
What would need to be true (bull case)
- If ulixacaltamide and relutrigine receive approval, the company could become a multi-product neurology company with indications that have unmet medical needs 23.
- The genetic platform and several breakthrough designations could support value creation beyond the first candidates 13.
- A cash reserve covering operations into 2028 could allow several programs to run in parallel without immediate new funding 3.
What would break the thesis
What to watch
- Decizia FDA pentru ulixacaltamidJanuary 2027
- Rezultatele studiului EMERALDQ4 2026
- FDA decision on relutrigineDecember 2026
- FDA decision on ulixacaltamideJanuary 2027
- Topline results of the EMERALD studyQ4 2026
- Restart of POWER2 and launch of POWER3 with vormatrigineQ4 2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Praxis is a fully integrated, central nervous system biopharmaceutical company that translates insights from genetic epilepsies into therapies for disorders characterized by excitation-inhibition imbalance in the brain 1. Its activity rests on two proprietary platforms: Cerebrum™, for oral small molecules, and Solidus™, for antisense oligonucleotides, each with several programs in development 1. The company has not yet generated product sales and operates on a 'virtual' research model that relies on external collaborators and contract research organizations 12.
The clinical portfolio includes four candidates at a late clinical stage, three small molecules from the Cerebrum™ platform and one ASO from the Solidus™ platform, elsunersen 12. Ulixacaltamide, for essential tremor, and relutrigine, for developmental epileptic encephalopathies, have marketing applications filed with the FDA, with target decision dates in the second half of 2026 and early 2027, respectively 23. Vormatrigine did not meet its primary endpoint in the POWER1 study, and the company is restarting the POWER2 study with a revised approach 23.
The company's strategy is based on targets identified through human genetics, translational tools such as EEG biomarkers and transgenic animal models, and efficient clinical development toward proof of concept in patients 1. Operating losses are significant and are likely to persist over the long term as the company prepares its commercial launches 12.
Segments
Cerebrum™ (small molecules)
The Cerebrum™ platform includes ulixacaltamide, a selective inhibitor of T-type calcium channels developed for essential tremor, and relutrigine, a modulator of persistent sodium current for developmental epileptic encephalopathies 12. Vormatrigine, in the ENERGY program, is under reassessment after the POWER1 study results 23.
Solidus™ (ASO)
The Solidus™ platform's lead clinical candidate is elsunersen, for early-onset SCN2A developmental epileptic encephalopathy, which reported positive results in the EMBRAVE Part A study and received a Breakthrough Therapy Designation from the FDA 23. The company has three further ASOs at a preclinical stage, with development candidate nominations expected in 2026 12.
Vormatrigine (program under development)
Vormatrigine is in the ENERGY program for focal onset seizures and generalized epilepsy, and the POWER1 study missed its primary endpoint while achieving a secondary endpoint 23. The company paused enrollment in POWER2 to reassess the program, with restart planned for the fourth quarter of 2026 23.
Market context
Essential tremor is one of the most common movement disorders, with an estimated population of about seven million people in the United States, and available treatments have limited efficacy and tolerability 13. Developmental epileptic encephalopathies affect approximately 200,000 patients in the United States, a segment with unmet medical needs where precision therapies could become relevant if approvals are confirmed 1.
Commercial size depends on regulatory approvals, the pricing and reimbursement obtained, and the company's ability to build a sales force, areas the company describes as preparations under way 23. The exact market size and sales projections are not available in the analyzed sources.
Trends
- Precision therapies based on geneticstailwind
The identification of more than 900 genes associated with epilepsy provides a basis for medicines targeted at genetic causes, and some developmental epileptic encephalopathies have a single implicated gene 1. If this approach translates into approvals, it could support the value of the company's platforms.
- Regulatory requirements and delaysheadwind
The FDA extended the review period for the relutrigine NDA after additional sensitivity analyses were submitted, moving the target date to December 2026 23. Similar delays could postpone planned launches.
- Equity-based financingmixed
The company has financed itself mainly through equity issuance, and a January 2026 follow-on offering contributed to the increase in its cash reserve 23. Dependence on capital markets could limit flexibility if clinical objectives are not met.
- Preparation for commercial launchesmixed
The company is building commercial infrastructure for ulixacaltamide and relutrigine, including leadership teams, distribution and patient support programs 3. Administrative expenses have risen considerably, reflecting this preparation but also pressure on profitability 3.
Competitive position
For essential tremor, propranolol is the only approved drug, with limited efficacy and tolerability, and other beta-blockers and anticonvulsants are used off-label 1. For epileptic encephalopathies, standard sodium channel blockers can cause significant adverse effects, leaving room for more selective therapies 1.
The analyzed sources do not explicitly identify other developers competing in the same indications, which limits the comparative analysis. Real competition could come from other therapies in development for the same disorders, including platforms of other companies with similar programs 12.
- Propranolol (standard therapy for essential tremor)
The only approved treatment for essential tremor, with limited efficacy and tolerability according to the company 1.
- Beta-blockers and anticonvulsants used off-label
Used in essential tremor without specific approval, with limited efficacy according to the company 1.
- Standard sodium channel blockers
Existing treatments for epileptic encephalopathies that can cause significant adverse effects at therapeutic concentrations 1.
- Ulixacaltamide licensing partner in China
A China-based company that received exclusive development and commercialization rights for ulixacaltamide in its region 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Current report07 Jul 2026Other events
- Current report02 Jul 2026Item 4.01 · Financial statements and exhibits
- Current report29 Jun 2026Other events
- Current report22 Jun 2026Other events
- Current report12 Jun 2026Shareholder vote
- Current report01 Jun 2026Other events
- Current report07 May 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report07 May 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Praxis Precision Medicines, Inc. · 19 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Praxis Precision Medicines, Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Praxis Precision Medicines, Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.